Dr. Song described the mission of the new center as aggressive development of new, patented stem cell therapies along with the development of processes and protocols that follow stringent implementation of international quality benchmarks. He noted the center will have three main goals: adult stem cell collection and storage, establishment of processes and protocols based on international standards such as the American Association of Blood Banks (AABB), the Foundation for the Accreditation of Cellular Therapy (FACT) standards and ISO9001 certifications, and to patent and bring stem cell therapies to clinical practice.
Dr. Shengqin Ye, CEO of Jiangsu Beike Biotech, said Beike's recruitment of the world-renowned cyropreservation scientist, Dr. Ying Song, to serve as the center's Chief Scientific Officer is evidence of Beike's commitment to quality and safety. Dr. Ye said, "We are very pleased to have Dr. Song leading the charge to establish rigorous quality system and stem cell industrialization specifications. Dr. Song's wide breadth of expertise and experience in the United States are key assets as Beike refines stem cell banking protocols and conducts clinical trials."
In addition to his quality management and banking/tissue efforts, Dr.
Song's work with Beike includes oversight and coordination of the company's
R&D and pu
|SOURCE Beike Biotechnology Company Limited|
Copyright©2010 PR Newswire.
All rights reserved